HAMPTON, N.J., Feb. 13, 2017 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today upcoming investor events for February and March.

Upcoming Investor Conferences

Anthony Marucci, Co-founder, President and Chief Executive Officer, and Thomas Davis, M.D., Executive Vice President and Chief Medical Officer, will participate in presentations at the following conferences:
  • Leerink Partners 6th Annual Global Healthcare Conference on Wednesday, February 15, 2017 at 9:30 a.m. EST in New York - fireside chat 
  • Cowen and Company 37th Annual Health Care Conference on Tuesday, March 7, 2017 at 9:20 a.m. EST in Boston - corporate presentation

Live webcasts of the presentations will be available on the "Events & Presentations" page of the "Investors & Media" section of the Celldex website. A replay of the presentations will be available for seven days following each event.

2016 Year-End Results and Conference Call/Webcast
  • Celldex will release fourth quarter and year-end 2016 financial results on Tuesday, March 14, 2017 after the U.S. financial markets close.  
  • Celldex will host a conference call/webcast at 4:30 p.m. EDT on the same day to provide an in-depth update on its pipeline and upcoming milestones for 2017.

Event details, including conference call phone numbers, can be accessed on the "Events & Presentations" page under the "Investors & Media" section of the Celldex website.

About Celldex Therapeutics, Inc.Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response. Visit www.celldex.com.

If you liked this article you might like

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

2016 Was a Terrible Year for Biotech but the Tweets Were on Point

Corbus Pharma Bear Thesis Is Alive and Well on Sclerosis Drug Data Skewed Positive

Celldex Therapeutics (CLDX) Stock Up on Q2 Results

Celldex Therapeutics (CLDX) Is Strong On High Volume Today